Paper: "Nationally, leucovorin use increased in 2025 following the media attention and the FDA announcement, with larger increases for younger groups. Mean leucovorin use increased by 1348% among those aged 0 to 10 years (385 prescriptions/week before February 2025 to 5575/week after the FDA announcement) and by 470% among those aged 11 to 20 years (514/week to 2928/week)."

Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards - story by @dariustahir

Employers begin to back-track on GLP-1 coverage - as @rorynotsorry has long said, this is an affordability issue and dropping insurance coverage of these drugs will only push more people to the research use market and hopefully to safe vendors.

HHS OIG Report on prior auth and appeals denial rate by insurer - staggering numbers. Think of the burden created on providers, families, patients, the millions of house spent fighting medical necessity with payer bots.

Epitalon has become a popular peptide in some circles. Could the current dosing protocols be off by an order of magnitude due to mis-application of original studies? Intriguing paper: "the 5 to 10 mg human dosing paradigm originates from studies conducted with Epithalamin, a crude polypeptide extract of bovine pineal glands, rather than with Epitalon itself. Primate data comparing both compounds reveal a model- and endpoint-specific potency differential of approximately 500-fold. Taken together, these findings support the testable translational hypothesis that Epitalon should be evaluated in the low microgram range, approximately 100 to 300 μg per treatment day, with treatment schedule and frequency to be defined in formal dose-finding studies, rather than the milligram range currently employed. The current practice may represent systematic overdosing rooted in the historical conflation of a crude extract with a purified synthetic peptide." cc @AbudBakri